Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/65865
Título: | Coadjuvant anti-VEGF A therapy improves survival in patients with colorectal cancer with liver metastasis: a systematic review |
Autor(es): | Novo, Isabel Campos, Bárbara Pinto-Ribeiro, Filipa Martins, Sandra |
Palavras-chave: | anti-VEGF colorectal cancer hepatic metastasis survival |
Data: | 18-Abr-2020 |
Editora: | Multidisciplinary Digital Publishing Institute |
Revista: | Gastrointestinal Disorders |
Citação: | Novo, I.; Campos, B.; Pinto-Ribeiro, F.; Martins, S.F. Coadjuvant Anti-VEGF A Therapy Improves Survival in Patients with Colorectal Cancer with Liver Metastasis: A Systematic Review. Gastrointest. Disord. 2020, 2, 71-85. |
Resumo(s): | Background: the presence of liver metastasis in colorectal cancer (CRC) remains one of the most significant prognostic factors. Objective: systematically review the results of studies evaluating the benefit of adding bevacizumab to a normal chemotherapy regime in the survival of patients with colorectal-cancer liver metastasis (CRLM). Search methods: Pubmed and Google Scholar databases were searched for eligible articles (from inception up to the 2 April 2019). Inclusion criteria: studies including patients with CRLM receiving anti-vascular endothelial growth factor (VEGF; bevacizumab) as treatment, overall survival as an outcome; regarding language restrictions, only articles in English were accepted. Main results: Eleven studies met the inclusion criteria. In 73% of these cases, chemotherapy with bevacizumab was an effective treatment modality for treating CRLM, and its administration significantly extended both overall survival (OS) and/or progression-free survival (PFS). Nevertheless, three articles showed no influence on survival rates of bevacizumab-associated chemotherapy. Author conclusions: It is necessary to standardize methodologies that aim to evaluate the impact of bevacizumab administration on the survival of patients with CRLM. Furthermore, follow-up time and the cause of a patient’s death should be recorded, specified, and cleared in order to better calculate the survival rate and provide a comparison between the produced literature. |
Tipo: | Artigo |
URI: | https://hdl.handle.net/1822/65865 |
DOI: | 10.3390/gidisord2020007 |
e-ISSN: | 2624-5647 |
Versão da editora: | https://www.mdpi.com/2624-5647/2/2/7 |
Arbitragem científica: | yes |
Acesso: | Acesso aberto |
Aparece nas coleções: | ICVS - Artigos em revistas internacionais / Papers in international journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
gastrointestdisord-02-00007.pdf | 1,01 MB | Adobe PDF | Ver/Abrir |
Este trabalho está licenciado sob uma Licença Creative Commons